The reporter learned today from the State Drug Administration that the latest statistics show that in the first half of this year, China approved the launch of 38 Class 1 innovative drugs. Among them, the proportion of drugs with new targets and innovative mechanisms independently developed by China has increased dramatically. Lan Gongtao, deputy director of the Drug Registration Administration Department of the State Drug Administration, said that by the end of June, the State Drug Administration had approved 2,318 drug marketing registration applications this year, including 38 “new global” innovative drugs, including 20 chemicals, 17 biological products, and 1 traditional Chinese medicine.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.